FDA Clears IND, Opening Acute MS Relapse Path for Privosegtor
OCS is trading near its 52-week low of $6.78 (13% above the low).
Summary
The FDA cleared the IND for Privosegtor in acute MS relapses, letting Oculis cross-reference data from its existing ophthalmology IND and run a trial with a primary endpoint as early as three months at the same 3mg/kg daily dose for five days used in PIONEER-1. The expansion rests on the completed Phase 2 ACUITY study, where the drug improved visual function, preserved retinal ganglion cell layer integrity, and cut NfL and GFAP blood levels. Oculis frames this as a large unmet need: roughly 2.8 million people have MS worldwide and an estimated 170,000 relapses occur annually in the U.S., with no approved neuroprotective therapy for acute attacks. It is a pipeline-expansion win for a small-cap name, not a revenue event — Privosegtor remains investigational and the registrational PIONEER program in optic neuropathies is still the nearer-term value driver. The company hosts an R&D Day on December 8, 2026, to detail the pivotal plan for acute MS relapses and update on PIONEER.
At the time of this announcement, OCS was trading at $7.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $471.6M. The 52-week trading range was $6.78 to $34.48. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.